Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness Does Not Meet Efficacy Endpoints

Vir Biotechnology has released the topline data from its Phase 2 PENINSULA trial, which evaluated VIR-2482 for the prevention of seasonal influenza A illness. According to the announcement made on July 20, 2023, VIR BIOTECHNOLOGY Inc. reported that the trial did not meet its primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), there was a..